Leuprolide - Uses, Dosage, Side Effects, Interaction

Leuprolide Acetate is the acetate salt of a synthetic nonapeptide analog of the gonadotropin-releasing hormone. A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE, and FOLLICLE STIMULATING HORMONE. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.

Leuprolide acetate is an acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long-lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analog of gonadotropin-releasing hormone and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. It has a role as an antineoplastic agent and a gonadotropin-releasing hormone agonist. It contains leuprolide.

Leuprolide is a synthetic 9-residue peptide analog of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.^[rx,rx]

Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron by Abbvie Endocrine Inc.^[rx] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.^[rx,rx] Leuprolide remains frontline therapy in all conditions for which it is indicated for use.

Mechanism of Action

Like naturally occurring luteinizing hormone-releasing hormone, initial or intermittent administration of leuprolide stimulates the release of luteinizing hormone and follicle-stimulating hormone from the anterior pituitary.

Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect the downstream synthesis and release of the sex hormones testosterone, dihydrotestosterone, estrone, and estradiol.^[rx]

Despite the variety of conditions indicated for treatment with leuprolide, the mechanism of action underlying efficacy is the same in all cases. As a GnRHR agonist, leuprolide binds to and initially activates downstream LH and FSH release; this initial spike in gonadotropin levels is responsible for some of the adverse effects associated with treatment. After 2-4 weeks of treatment, continuous stimulation of GnRHR results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation

Luteinizing hormone and follicle-stimulating hormone release from the anterior pituitary transiently increase testosterone concentration in males. However, continuous administration of leuprolide in the treatment of prostatic carcinoma suppresses the secretion of gonadotropin-releasing hormone, with a resultant fall in testosterone concentrations and a “medical castration”.

Initial stimulation of gonadotropins from the anterior pituitary is followed by prolonged suppression. Gonadotropin release from the anterior pituitary transiently increases estrone and estradiol concentrations in females. However, continuous administration of leuprolide in the treatment of endometriosis produces a fall in estrogens to postmenopausal levels. As a consequence of the suppression of ovarian function, both normal and ectopic endometrial tissues become inactive and atrophic. As a result, amenorrhea occurs.

Indications

Antineoplastic Agents, Hormonal; Fertility Agents, Female. Leuprolide is indicated for the palliative treatment of advanced prostatic cancer, especially as an alternative to orchiectomy or estrogen administration.
Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.
Leuprolide is indicated for the treatment of advanced prostate cancer and as a palliative treatment of advanced prostate cancer. It is also used for the treatment of pediatric patients with central precocious puberty (CPP). In combination with oral norethisterone (also known as norethindrone), leuprolide is also indicated for the initial treatment of the symptoms of endometriosis.^[rx] Finally, in combination with iron supplementation, leuprolide is indicated for the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).^[rx]
Advanced Prostate Cancer
Anemia
Central Precocious Puberty (CPP)
Endometriosis

Leuprolide is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions. Leuprolide is about 30 times more active than natural gonadotropin-releasing hormone … and 100 times more active than gonadorelin.

Contraindications

spread of cancer to the spinal column
diabetes
high cholesterol
low amount of magnesium in the blood
low amount of potassium in the blood
overweight
depression
high blood pressure
a heart attack
prolonged QT interval on EKG
chronic heart failure
abnormal EKG with QT changes from birth
a stroke
liver problems
decreased calcification or density of bone
seizures
pregnancy
obstruction of any part of the urinary tract
tobacco smoking

Dosage

Strengths: 7.5 mg/month; 22.5 mg/3 months; 45 mg/6 months; 30 mg/4 months; 65 mg; 11.25 mg/month; 15 mg/month; 3.75 mg/month; 11.25 mg/3 months; 30 mg/3 months; 5 mg/mL; 1 mg/0.2 mL; 7.5 mg; 3.75 mg; 42 mg/6 months.

Prostate Cancer

IM: LUPRON DEPOT:

7.5 mg IM once a month OR
22.5 mg IM every 3 months OR
30 mg IM every 4 months OR
30 mg IM every 6 months

IMPLANT:
VIADUR IMPLANT:

65 mg inserted subcutaneously in the inner aspect of the upper arm every 12 months

SUBCUTANEOUS:
CAMCEVI:

42 mg subcutaneously every 6 months

ELIGARD:

7.5 mg subcutaneously once a month OR
22.5 mg subcutaneously every 3 months OR
30 mg subcutaneously every 4 months OR
45 mg subcutaneously every 6 months
Treatment is usually continued in patients who are treated with gonadotropin-releasing hormone (GnRH) analogs and who develop non-metastatic and metastatic castration-resistant prostate cancer.
Implant: The manufacturer’s product information should be consulted regarding insertion and removal techniques.
Palliative treatment of advanced prostate cancer
Treatment of advanced prostate cancer

Endometriosis

IM: Endometriosis:
LUPRON DEPOT 3.75 mg:

Initial treatment: 3.75 mg IM once a month for up to 6 months
Retreatment: 3.75 mg IM once a month for 1 to 6 months
Duration of treatment: Up to 12 months

LUPRON DEPOT 11.25 mg: 11.25 mg IM every 3 months
Duration of treatment: Up to 12 months

Uterine Leiomyomata

3.75 mg IM once a month OR
11.25 mg IM once
Limitation of use: In women receiving this drug for endometriosis, the total duration of treatment with this drug and add-back hormone replacement therapy (norethindrone 5 mg) should be limited to 12 months to reduce bone mineral density loss and vasomotor symptoms.
Limitation of use: This drug has not been approved for use with norethindrone for the preoperative improvement of patients with anemia caused by heavy bleeding due to fibroids.
Management of endometriosis (including pain relief and reduction of endometriotic lesions)
With norethindrone for the initial management of endometriosis symptoms and for the management of recurrent symptoms
Preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata/fibroids

Uterine Leiomyomata

IM: Endometriosis
LUPRON DEPOT 3.75 mg

Initial treatment: 3.75 mg IM once a month for up to 6 months
Retreatment: 3.75 mg IM once a month for 1 to 6 months
Duration of treatment: Up to 12 months OR LUPRON DEPOT 11.25 mg: 11.25 mg IM every 3 months
Duration of treatment: Up to 12 months

Uterine Leiomyomata

3.75 mg IM once a month OR 11.25 mg IM once
Limitation of use: In women receiving this drug for endometriosis, the total duration of treatment with this drug and add-back hormone replacement therapy (norethindrone 5 mg) should be limited to 12 months to reduce bone mineral density loss and vasomotor symptoms.
Limitation of use: This drug has not been approved for use with norethindrone for the preoperative improvement of patients with anemia caused by heavy bleeding due to fibroids.
Management of endometriosis (including pain relief and reduction of endometriotic lesions)
With norethindrone for the initial management of endometriosis symptoms and for the management of recurrent symptoms
Preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata/fibroids

Pediatric Dose for Precocious Puberty

2 years and older:
IM INJECTION: 1-MONTH DEPOT INJECTION:

25 kg or less: 7.5 mg IM once a month
Greater than 25 kg to 37.5 kg: 11.25 mg IM once a month
Greater than 37.5 kg: 15 mg IM once a month

3-MONTH DEPOT INJECTION

11.25 or 30 mg IM every 3 months
Doses should be titrated to the individual.
Hormone levels should be tested after 1 to 2 months (for 1-month injections) OR after 2 to 3 months (for 3-month injections) of therapy and with each dose change to ensure adequate pituitary gonadotropin suppression.
Once a dose that results in adequate hormonal suppression has been determined, it can often be maintained for the duration of therapy in most children; however, hormonal suppression should be verified as weight can increase significantly while on therapy.
Therapy should be discontinued at the appropriate age of onset of puberty at the discretion of the physician.

SUBCUTANEOUS INJECTION:

Fensolvi: 45 mg subcutaneously every 6 months
NOTE: The short-acting formulation has been replaced with long-acting formulations.
The dosage should be adjusted for weight changes.
Discontinuation of therapy should be considered at the appropriate age for the onset of puberty.
Central precocious puberty (CPP) is defined as the early onset of secondary sexual characteristics (generally earlier than 8 years in girls and 9 years in boys) associated with pubertal pituitary gonadotropin activation; it may show a significantly advanced bone age that can result in diminished adult height.

Dose Adjustments

Pediatric patients: If adequate hormonal and clinical suppression is not reached with the starting dose, it should be increased to the next available higher dose (e.g., 11.25 mg or 15 mg at the next monthly injection).

Administration advice:

The injection site should be varied periodically.
Avoid areas with brawny or fibrous subcutaneous tissue or locations that could be rubbed or compressed (e.g., with a belt or clothing waistband)
The manufacturer’s product information should be consulted.

Side Effects

The Most Common

tiredness
hot flashes (a sudden wave of mild or intense body heat), sweating, or clamminess
breast tenderness, pain, or change in breast size in both men and women
vaginal discharge, dryness, or itching in women
spotting (light vaginal bleeding) or menstruation (periods)
decrease in the size of testicles
decrease in sexual ability or desire
swelling of the hands, feet, ankles, or lower legs
pain, burning, or tingling in the hands or feet
pain, burning, bruising, redness, or hardening at the place where the injection was given
change in weight
muscle or joint pain
runny nose, cough, sore throat, or flu-like symptoms
fever
stomach pain
constipation
headache
acne
depression
unable to control emotions and frequent mood changes
nervousness
a general feeling of discomfort or uneasiness
difficulty with memory
itching, rash, or hives
difficulty breathing or swallowing
pain in the arms, back, chest, neck, or jaw
slow or difficult speech
dizziness or fainting
weakness, numbness, or inability to move an arm or leg
bone pain
painful, frequent, or difficult urination
blood in urine
extreme thirst
weakness
dry mouth
nausea
vomiting
breath that smells fruity
decreased consciousness
sudden headache
blurred vision
vision changes
difficulty moving eyes
drooping eyelids
confusion
seizures

MORE COMMON

Arm, back, or jaw pain
bloody or cloudy urine
blurred vision
bone pain
chest pain or discomfort
difficult, burning, or painful urination
difficulty with moving
dizziness
frequent urge to urinate
headache
increased urge to urinate during the night
muscle pain or stiffness
nausea
nervousness
pain in the arms or legs
pain in the joints
pale skin
pounding in the ears
slow or fast heartbeat
sweating
unusual bleeding or bruising
unusual tiredness or weakness
waking to urinate at night
burning, numbness, tingling, or painful sensations
chest pain
cold, clammy, pale skin
confusion
dizziness or lightheadedness
double vision
dry mouth
flushed, dry skin
fruit-like breath odor
increased hunger
increased thirst
increased urination
irregular heartbeat
loss of consciousness
seizures
thoughts or attempts at killing oneself
unexplained weight loss
unsteadiness or awkwardness
visual changes
weakness in the arms, hands, legs, or feet
Anxiety

RARE

Pain in the groin or legs (especially in the calves)
Altered mental status
anxiety
blurred vision
deepening of voice
increased hair growth
mental depression
mood changes
Body aches or pain
chest tightness
chills
cough
cough producing mucus
difficulty in breathing
ear congestion
fever
headache
loss of voice
muscle aches
noisy breathing
pain or redness at the injection site
runny or stuffy nose
sneezing
sore throat
unusual tiredness or weakness
Irritability
mood or mental changes
Burning, itching, or swelling at the injection site
Blurred vision
change in ability to see colors, especially blue or yellow
nausea and vomiting
seizures
severe headache

Drug Interaction

DRUG	INTERACTION
Abacavir	Leuprolide may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.
Aceclofenac	Aceclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Acetaminophen	Leuprolide may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Acipimox	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Acipimox.
Aclidinium	Leuprolide may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Leuprolide.
Acyclovir	Acyclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Adenosine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Adenosine.
Ajmaline	The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Leuprolide.
Albiglutide	The therapeutic efficacy of Albiglutide can be decreased when used in combination with Leuprolide.
Albutrepenonacog	Leuprolide may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Aldesleukin	Leuprolide may decrease the excretion rate of Aldesleukin which could result in a higher serum level.
Alendronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid.
Alfuzosin	The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Leuprolide.
Alimemazine	The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Leuprolide.
Allopurinol	Leuprolide may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almasilate	Leuprolide may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Leuprolide may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.
Alprazolam	Leuprolide may decrease the excretion rate of Alprazolam which could result in a higher serum level.
Amantadine	The risk or severity of QTc prolongation can be increased when Amantadine is combined with Leuprolide.
Amifampridine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amifampridine.
Amikacin	Leuprolide may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	Aminophenazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Amiodarone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.
Amisulpride	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amisulpride.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amitriptyline.
Ammonium chloride	Leuprolide may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Leuprolide.
Amoxapine	The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Leuprolide.
Amoxicillin	Leuprolide may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Leuprolide may decrease the excretion rate of Amphetamine which could result in a higher serum level.
Amphotericin B	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Amphotericin B.
Ampicillin	Leuprolide may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Amrinone	Leuprolide may decrease the excretion rate of Amrinone which could result in a higher serum level.
Anagrelide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.
Ancestim	Leuprolide may decrease the excretion rate of Ancestim which could result in a higher serum level.
Antazoline	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Antazoline.
Antihemophilic	Leuprolide may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antipyrine	Antipyrine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Antithrombin	Leuprolide may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antrafenine	Antrafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Apalutamide	Leuprolide may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apomorphine	The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Leuprolide.
Apremilast	Leuprolide may decrease the excretion rate of Apremilast which could result in a higher serum level.
Arformoterol	The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Leuprolide.
Aripiprazole	The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide.
Aripiprazole lauroxil	The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Leuprolide.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.
Artemether	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.
Articaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Articaine.
Asenapine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.
Astemizole	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Astemizole.
Atazanavir	The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Leuprolide.
Atomoxetine	The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Leuprolide.
Atorvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Atorvastatin.
Atropine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Atropine.
Auranofin	Leuprolide may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Leuprolide may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Azacitidine	Leuprolide may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Azatadine	The risk or severity of QTc prolongation can be increased when Azatadine is combined with Leuprolide.
Azathioprine	Leuprolide may decrease the excretion rate of Azathioprine which could result in a higher serum level.
Azelaic acid	Leuprolide may decrease the excretion rate of Azelaic acid which could result in a higher serum level.
Azithromycin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Azithromycin.
Aztreonam	Leuprolide may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Bacitracin	Bacitracin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Baclofen	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Baclofen.
Balsalazide	Balsalazide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Baricitinib	Leuprolide may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Bedaquiline	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bedaquiline.
Bendroflumethiazide	Bendroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Benserazide	Leuprolide may decrease the excretion rate of Benserazide which could result in a higher serum level.
Benzatropine	The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Leuprolide.
Benznidazole	Leuprolide may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Benzocaine.
Benzthiazide	Benzthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Benzyl alcohol.
Bepotastine	Leuprolide may decrease the excretion rate of Bepotastine which could result in a higher serum level.
Bepridil	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bepridil.
Berotralstat	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Berotralstat.
Betamethasone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Betamethasone.
Bezafibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Bezafibrate.
Bicisate	Leuprolide may decrease the excretion rate of Bicisate which could result in a higher serum level.
Bilastine	The risk or severity of QTc prolongation can be increased when Bilastine is combined with Leuprolide.
Bismuth subgallate	Leuprolide may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.
Bisoprolol	Leuprolide may decrease the excretion rate of Bisoprolol which could result in a higher serum level.
Bisoxatin	Leuprolide may decrease the excretion rate of Bisoxatin which could result in a higher serum level.
Bleomycin	Leuprolide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Bortezomib	The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Leuprolide.

Bretylium	The risk or severity of QTc prolongation can be increased when Bretylium is combined with Leuprolide.
Brivaracetam	Leuprolide may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Bromazepam	Leuprolide may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Bromocriptine	The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Leuprolide.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Brompheniramine	The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Leuprolide.
Buclizine	The risk or severity of QTc prolongation can be increased when Buclizine is combined with Leuprolide.
Budesonide	Leuprolide may decrease the excretion rate of Budesonide which could result in a higher serum level.
Bumadizone	Bumadizone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Bupivacaine.
Bupropion	Leuprolide may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buserelin	The risk or severity of QTc prolongation can be increased when Buserelin is combined with Leuprolide.
Buspirone	Leuprolide may decrease the excretion rate of Buspirone which could result in a higher serum level.
Butabarbital	Leuprolide may decrease the excretion rate of Butabarbital which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Butamben.
Butriptyline	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Butriptyline.
Canagliflozin	The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	Leuprolide may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Capreomycin	Leuprolide may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capromab pen	Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Capsaicin.
Captopril	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Captopril.
Carbamazepine	Leuprolide may decrease the excretion rate of Carbamazepine which could result in a higher serum level.
Carbidopa	Leuprolide may decrease the excretion rate of Carbidopa which could result in a higher serum level.
Carbimazole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Carbimazole.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Carbinoxamine.
Carboplatin	Carboplatin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Carmustine	Leuprolide may decrease the excretion rate of Carmustine which could result in a higher serum level.
Carprofen	Carprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefaclor	Cefaclor may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefdinir	Leuprolide may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceftolozane	Leuprolide may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Celiprolol	The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Leuprolide.
Cephalexin	Cephalexin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ceritinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ceritinib.
Cerivastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cerivastatin.
Certolizumab p	Leuprolide may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.
Cetirizine	The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Leuprolide.
Cevimeline	Leuprolide may decrease the excretion rate of Cevimeline which could result in a higher serum level.
Chloral hydrate	Leuprolide may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.
Chlorcyclizine	The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Leuprolide.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Chloroprocaine.
Chloroquine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chloroquine.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorpheniramine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpheniramine.
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Chlorpromazine.
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.
Chlorprothixene	The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Leuprolide.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Leuprolide may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.
Choline C 11	Leuprolide may decrease effectiveness of Choline C 11 as a diagnostic agent.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Choline salicylate	Leuprolide may decrease the excretion rate of Choline salicylate which could result in a higher serum level.
Chondroitin sulfate	Leuprolide may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.
Chromic chloride	Leuprolide may decrease the excretion rate of Chromic chloride which could result in a higher serum level.
Chromic nitrate	Leuprolide may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.
Chromium	Leuprolide may decrease the excretion rate of Chromium which could result in a higher serum level.
Chromium gluconate	Leuprolide may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.
Chromium nicoti	Leuprolide may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.
Chromous sulfate	Leuprolide may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.
Cidofovir	Cidofovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Cilostazol	The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Leuprolide.
Cimetidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Cinchocaine.
Cinnarizine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinnarizine.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cinoxacin.
Ciprofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ciprofibrate.

You Might Also Read Abatacept; Uses, Dosage, Side Effects, Drug Interactions

Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ciprofloxacin.
Cisapride	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Cisapride.
Cisplatin	Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Citalopram	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Citalopram.
Cladribine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cladribine.
Clarithromycin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clarithromycin.
Clemastine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clemastine.
Clevidipine	Leuprolide may decrease the excretion rate of Clevidipine which could result in a higher serum level.
Clobazam	Leuprolide may decrease the excretion rate of Clobazam which could result in a higher serum level.
Clofarabine	Leuprolide may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofazimine	The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Leuprolide.
Clofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Clofibrate.
Clomipramine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clomipramine.
Clonazepam	Leuprolide may decrease the excretion rate of Clonazepam which could result in a higher serum level.
Clorazepic acid	Leuprolide may decrease the excretion rate of Clorazepic acid which could result in a higher serum level.
Clove oil	Leuprolide may decrease the excretion rate of Clove oil which could result in a higher serum level.
Clozapine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Cocaine.
Colchicine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Colchicine.
Colistimethate	Colistimethate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Colistin	Leuprolide may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated estro	Leuprolide may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Corifollitropin a	The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Leuprolide.
Crizotinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Crizotinib.
Cyanocobalamin	Leuprolide may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.
Cyclizine	The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Leuprolide.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Cyclosporine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Cyproheptadine	The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Leuprolide.
Cytarabine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine.
Dabigatran etexi	Leuprolide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dabrafenib	The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Leuprolide.
Dacarbazine	Leuprolide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Dalfampridine	Leuprolide may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dapagliflozin	The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide.
Daptomycin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Daptomycin.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Leuprolide.
Dasatinib	The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Leuprolide.
Deferiprone	Leuprolide may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Degarelix	The risk or severity of QTc prolongation can be increased when Degarelix is combined with Leuprolide.
Delafloxacin	The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Leuprolide.
Delamanid	Leuprolide may increase the QTc-prolonging activities of Delamanid.
Desflurane	The risk or severity of QTc prolongation can be increased when Desflurane is combined with Leuprolide.
Desipramine	The risk or severity of QTc prolongation can be increased when Desipramine is combined with Leuprolide.
Desloratadine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Desloratadine.
Desmopressin	Leuprolide may decrease the excretion rate of Desmopressin which could result in a higher serum level.
Desvenlafaxine	Leuprolide may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Deutetrabenazine.
Dexamethasone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Dexamethasone.
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Leuprolide.
Dexchlorpheniramine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine maleate.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Dexmedetomidine	Leuprolide may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.
Dexpanthenol	Leuprolide may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	Leuprolide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Dextran	Leuprolide may decrease the excretion rate of Dextran which could result in a higher serum level.
Diatrizoate	Leuprolide may decrease the excretion rate of Diatrizoate which could result in a higher serum level.
Diazepam	Leuprolide may decrease the excretion rate of Diazepam which could result in a higher serum level.
Dichlorobenzyl alcohol	Leuprolide may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Dicyclomine	Leuprolide may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Didanosine	Leuprolide may decrease the excretion rate of Didanosine which could result in a higher serum level.
Dienogest	Leuprolide may decrease the excretion rate of Dienogest which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Difluocortolone	Leuprolide may decrease the excretion rate of Difluocortolone which could result in a higher serum level.
Digitoxin	The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Leuprolide.
Digoxin	Leuprolide may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Diltiazem	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Diltiazem.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dimenhydrinate.
Dimercaprol	Leuprolide may decrease the excretion rate of Dimercaprol which could result in a higher serum level.
Dimethyl sulfoxide	Leuprolide may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Diphenhydramine.
Disopyramide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide.
Disulfiram	The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Leuprolide.
DL-Methylephedrine	Leuprolide may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.
Dobutamine	Leuprolide may decrease the excretion rate of Dobutamine which could result in a higher serum level.
Docetaxel	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Docetaxel.
Dofetilide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dofetilide.
Dolasetron	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dolasetron.
Domperidone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Domperidone.
Dopamine	Leuprolide may decrease the excretion rate of Dopamine which could result in a higher serum level.
Doripenem	Leuprolide may decrease the excretion rate of Doripenem which could result in a higher serum level.
Dosulepin	The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Leuprolide.
Doxacurium	Leuprolide may decrease the excretion rate of Doxacurium which could result in a higher serum level.
Doxepin	The risk or severity of QTc prolongation can be increased when Doxepin is combined with Leuprolide.
Doxycycline	Leuprolide may decrease the excretion rate of Doxycycline which could result in a higher serum level.
Doxylamine	The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Leuprolide.
Dronedarone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dronedarone.
Droperidol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Droperidol.
Drospirenone	Drospirenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Droxidopa	Leuprolide may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.
Duloxetine	Leuprolide may decrease the excretion rate of Duloxetine which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Dyclonine.
Dyphylline	Leuprolide may decrease the excretion rate of Dyphylline which could result in a higher serum level.

Ebastine	The risk or severity of QTc prolongation can be increased when Ebastine is combined with Leuprolide.
Edoxaban	Leuprolide may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Leuprolide may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efavirenz	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Efavirenz.
Eliglustat	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Eliglustat.
Emedastine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Emedastine.
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.
Enalapril	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Enalapril.
Enalaprilat	Leuprolide may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Encainide	The risk or severity of QTc prolongation can be increased when Encainide is combined with Leuprolide.
Encorafenib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Encorafenib.
Enoxacin	The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Leuprolide.
Entrectinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entrectinib.
Enzalutamide	Leuprolide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Epinastine	The risk or severity of QTc prolongation can be increased when Epinastine is combined with Leuprolide.
Eplerenone	Eplerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	Leuprolide may decrease the excretion rate of Epoprostenol which could result in a higher serum level.
Eprosartan	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Eprosartan.
Eribulin	The risk or severity of QTc prolongation can be increased when Eribulin is combined with Leuprolide.
Erlotinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erlotinib.
Ertapenem	Leuprolide may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Ertugliflozin	The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Leuprolide.
Erythromycin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Leuprolide.
Escitalopram	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Escitalopram.
Esmolol	The risk or severity of QTc prolongation can be increased when Esmolol is combined with Leuprolide.
Estazolam	Leuprolide may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estradiol	Leuprolide may decrease the excretion rate of Estradiol which could result in a higher serum level.
Estradiol acetate	Leuprolide may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.
Estradiol cypionate	Leuprolide may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.
Estradiol dienanthate	Leuprolide may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.
Estradiol valerate	Leuprolide may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.
Estrone sulfate	Leuprolide may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.
Eszopiclone	Leuprolide may decrease the excretion rate of Eszopiclone which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Leuprolide may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Ethambutol	Leuprolide may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Ethanol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ethanol.
Ethosuximide	The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Leuprolide.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Etomidate	Leuprolide may decrease the excretion rate of Etomidate which could result in a higher serum level.
Etonogestrel	Leuprolide may decrease the excretion rate of Etonogestrel which could result in a higher serum level.
Etoricoxib	Etoricoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Eucalyptus oil	Leuprolide may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.
Ezogabine	The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Leuprolide.
Famotidine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Leuprolide.
Felbamate	The risk or severity of QTc prolongation can be increased when Felbamate is combined with Leuprolide.
Felodipine	The risk or severity of QTc prolongation can be increased when Felodipine is combined with Leuprolide.
Fenbufen	Fenbufen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Fenofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibrate.
Fenofibric acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fenofibric acid.
Fenoldopam	Leuprolide may decrease the excretion rate of Fenoldopam which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Fentanyl	Leuprolide may decrease the excretion rate of Fentanyl which could result in a higher serum level.
Fesoterodine	Leuprolide may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fexinidazole	The risk or severity of adverse effects can be increased when Leuprolide is combined with Fexinidazole.
Finerenone	Finerenone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Flavoxate	Leuprolide may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flecainide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flecainide.
Floctafenine	Floctafenine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Florbetaben (18F)	Leuprolide may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.
Florbetapir (18F)	Leuprolide may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.
Floxuridine	Leuprolide may decrease the excretion rate of Floxuridine which could result in a higher serum level.
Fluconazole	The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Leuprolide.
Flucytosine	Leuprolide may decrease the excretion rate of Flucytosine which could result in a higher serum level.
Fludeoxyglucose	Leuprolide may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.
Flumazenil	Leuprolide may decrease the excretion rate of Flumazenil which could result in a higher serum level.
Fluocinolone acetonide	Leuprolide may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.
Fluorouracil	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluorouracil.
Fluoxetine	The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Leuprolide.
Flupentixol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Flupentixol.
Flurazepam	Leuprolide may decrease the excretion rate of Flurazepam which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Fluspirilene	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Fluspirilene.
Flutamide	Leuprolide may decrease the excretion rate of Flutamide which could result in a higher serum level.
Fluvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fluvastatin.
Fluvoxamine	Leuprolide may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.
Folic acid	Leuprolide may decrease the excretion rate of Folic acid which could result in a higher serum level.
Fomepizole	Leuprolide may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Leuprolide may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Formestane	Leuprolide may decrease the excretion rate of Formestane which could result in a higher serum level.
Formoterol	The risk or severity of QTc prolongation can be increased when Formoterol is combined with Leuprolide.
Foscarnet	The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Leuprolide.
Fosfomycin	Leuprolide may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Fosinopril	Leuprolide may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Fostemsavir	The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Leuprolide.
Framycetin	Framycetin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Furosemide	Furosemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Fusidic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Fusidic acid.
Gabapentin enacar	Leuprolide may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gadobenic acid.
Gadodiamide	Leuprolide may decrease the excretion rate of Gadodiamide which could result in a higher serum level.
Gadofosveset trisodium	Leuprolide may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Leuprolide may decrease the excretion rate of Gadopentetic acid which could result in a higher serum level.
Gadoteric acid	Leuprolide may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Leuprolide may decrease the excretion rate of Gadoteridol which could result in a higher serum level.
Galantamine	The risk or severity of QTc prolongation can be increased when Galantamine is combined with Leuprolide.

Ganciclovir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ganciclovir.
Gatifloxacin	The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Leuprolide.
Gemcitabine	Leuprolide may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Gemfibrozil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Gemfibrozil.
Gemifloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gemifloxacin.
Gentamicin	Leuprolide may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gilteritinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Gilteritinib.
Gimeracil	Leuprolide may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Glasdegib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Glasdegib.
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.
Glycerol phenyl	Leuprolide may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Glymidine	The therapeutic efficacy of Glymidine can be decreased when used in combination with Leuprolide.
Golodirsen	Leuprolide may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Goserelin.
Granisetron	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Granisetron.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Grepafloxacin.
Guanethidine	Leuprolide may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Leuprolide may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Halofantrine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Halofantrine.
Haloperidol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol.
Histrelin	The risk or severity of QTc prolongation can be increased when Histrelin is combined with Leuprolide.
Hydralazine	Leuprolide may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Leuprolide may decrease the excretion rate of Hydromorphone which could result in a higher serum level.
Hydroxocobalamin	Leuprolide may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Leuprolide.
Hydroxyethyl Starch	Leuprolide may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyzine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Hydroxyzine.
Hyoscyamine	The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Leuprolide.
Ibandronate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ibandronate.
Ibuprofen	Ibuprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ibutilide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ibutilide.
Icatibant	Leuprolide may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Idarucizumab	Leuprolide may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Leuprolide may decrease the excretion rate of Idebenone which could result in a higher serum level.
Ifosfamide	Leuprolide may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Iloperidone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Iloperidone.
Iloprost	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Iloprost.
Imatinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imatinib.
Imipramine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imipramine.
Indacaterol	The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Leuprolide.
Indapamide	Indapamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Indigotindisulfonic	Leuprolide may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.
Indinavir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Indinavir.
Indomethacin	Indomethacin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Infliximab	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Infliximab.
Inosine pranobex	Leuprolide may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Inositol	Leuprolide may decrease the excretion rate of Inositol which could result in a higher serum level.
Inotersen	The risk or severity of QTc prolongation can be increased when Inotersen is combined with Leuprolide.
Insulin aspart	The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Leuprolide.
Insulin beef	The therapeutic efficacy of Insulin beef can be decreased when used in combination with Leuprolide.
Insulin degludec	The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Leuprolide.
Insulin detemir	The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Leuprolide.
Insulin glargine	The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Leuprolide.
Insulin glulisine	The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Leuprolide.
Insulin human	The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide.
Insulin lispro	The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Leuprolide.
Insulin pork	The therapeutic efficacy of Insulin pork can be decreased when used in combination with Leuprolide.
Iobenguane sulfate	Leuprolide may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.
Iodixanol	Leuprolide may decrease the excretion rate of Iodixanol which could result in a higher serum level.
Ioflupane I-123	Leuprolide may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.
Iopromide	Leuprolide may decrease the excretion rate of Iopromide which could result in a higher serum level.
Iothalamic acid	Leuprolide may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.
Ioversol	Leuprolide may decrease the excretion rate of Ioversol which could result in a higher serum level.
Ioxilan	Leuprolide may decrease the excretion rate of Ioxilan which could result in a higher serum level.
Ipecac	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ipecac.
Ipilimumab	Leuprolide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Isoflurane	The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Leuprolide.
Isoniazid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isoniazid.
Isosorbide	Isosorbide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide monon	Leuprolide may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.
Isosulfan blue	Leuprolide may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.
Isotretinoin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Isotretinoin.
Isoxicam	Isoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Isradipine	The risk or severity of QTc prolongation can be increased when Isradipine is combined with Leuprolide.
Itraconazole	The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Leuprolide.
Ivabradine	Ivabradine may increase the QTc-prolonging activities of Leuprolide.
Ivermectin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ivermectin.
Ivosidenib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ivosidenib.
Ixazomib	Leuprolide may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Kanamycin	Leuprolide may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Ketamine	Leuprolide may decrease the excretion rate of Ketamine which could result in a higher serum level.
Ketazolam	Leuprolide may decrease the excretion rate of Ketazolam which could result in a higher serum level.
Ketoconazole	The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Leuprolide.
Ketoprofen	Ketoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Labetalol	Leuprolide may decrease the excretion rate of Labetalol which could result in a higher serum level.
Lacidipine	The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Leuprolide.
Lamivudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lamivudine.
Lamotrigine	The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Leuprolide.
Lapatinib	The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Leuprolide.
Latamoxef	Latamoxef may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ledipasvir	Leuprolide may decrease the excretion rate of Ledipasvir which could result in a higher serum level.

You Might Also Read Eribulin Mesylate; Uses, Dosage, Side Effects, Interactions

Lefamulin	Lefamulin may increase the QTc-prolonging activities of Leuprolide.
Leflunomide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Leflunomide.
Lenalidomide	Leuprolide may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Lenvatinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lenvatinib.
Lercanidipine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lercanidipine.
Lesinurad	Leuprolide may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Letrozole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Letrozole.
Levacetylmethadol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levacetylmethadol.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Levobupivacaine.
Levocabastine	The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Leuprolide.
Levocarnitine	Leuprolide may decrease the excretion rate of Levocarnitine which could result in a higher serum level.
Levocetirizine	The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Leuprolide.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levofloxacin.
Levomenthol	The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Leuprolide.
Levomilnacipran	Leuprolide may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Levosalbutamol	Leuprolide may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.
Levosimendan	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levosimendan.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Lidocaine.
Lidoflazine	The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Leuprolide.
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.
Liothyronine	Leuprolide may decrease the excretion rate of Liothyronine which could result in a higher serum level.
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.
Lisinopril	Leuprolide may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Lithium carbonate	Leuprolide may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Lixisenatide	The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Leuprolide.
Lofexidine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lofexidine.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lomefloxacin.
Loperamide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Loperamide.
Lopinavir	The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Leuprolide.
Loracarbef	Loracarbef may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Lorazepam	Leuprolide may decrease the excretion rate of Lorazepam which could result in a higher serum level.
Lorcaserin	Leuprolide may decrease the excretion rate of Lorcaserin which could result in a higher serum level.
Lornoxicam	Lornoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Lorpiprazole	Leuprolide may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.
Losartan	The risk or severity of QTc prolongation can be increased when Losartan is combined with Leuprolide.
Lovastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Lovastatin.
Loxoprofen	Loxoprofen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Lubiprostone	Leuprolide may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Lumefantrine.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Lurasidone	The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Leuprolide.
Macimorelin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Macimorelin.
Macitentan	Leuprolide may decrease the excretion rate of Macitentan which could result in a higher serum level.
Magnesium carbo	Leuprolide may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.
Magnesium chloride	Leuprolide may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.
Magnesium hydr	Leuprolide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium trisil	Leuprolide may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.
Mangafodipir	Leuprolide may decrease the excretion rate of Mangafodipir which could result in a higher serum level.
Mannitol	Mannitol may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Maprotiline	The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Leuprolide.
Mebeverine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mebeverine.
Mecamylamine	Leuprolide may decrease the excretion rate of Mecamylamine which could result in a higher serum level.
Mecasermin	The therapeutic efficacy of Mecasermin can be decreased when used in combination with Leuprolide.
Meclofenamic	Meclofenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Medroxyprogestero	Leuprolide may decrease the excretion rate of Medroxyprogesterone acetate which could result in a higher serum level.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Mefloquine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mefloquine.
Megestrol acetate	Leuprolide may decrease the excretion rate of Megestrol acetate which could result in a higher serum level.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Meloxicam.
Memantine	Leuprolide may decrease the excretion rate of Memantine which could result in a higher serum level.
Meperidine	Leuprolide may decrease the excretion rate of Meperidine which could result in a higher serum level.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Mepivacaine.
Mepyramine	The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Leuprolide.
Meropenem	Leuprolide may decrease the excretion rate of Meropenem which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mesoridazine.
Metamfetamine	Leuprolide may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Metaxalone	Leuprolide may decrease the excretion rate of Metaxalone which could result in a higher serum level.
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.
Methadone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Methadone.
Methazolamide	Methazolamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	Leuprolide may decrease the excretion rate of Methimazole which could result in a higher serum level.
Methotrexate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methotrexate.
Methotrimeprazine	The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Leuprolide.
Methoxsalen	Leuprolide may decrease the excretion rate of Methoxsalen which could result in a higher serum level.
Methoxy po	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Leuprolide.
Methsuximide	The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Leuprolide.
Methyldopa	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Methyldopa.
Methylene blue	Leuprolide may decrease the excretion rate of Methylene blue which could result in a higher serum level.
Methylnaltrexone	Leuprolide may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methyltestosterone	Leuprolide may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Metoclopramide.
Metolazone	Metolazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Leuprolide may decrease the excretion rate of Metoprolol which could result in a higher serum level.
Metronidazole	The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Leuprolide.
Metyrapone	Leuprolide may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Midazolam	Leuprolide may decrease the excretion rate of Midazolam which could result in a higher serum level.
Mifepristone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mifepristone.
Migalastat	Leuprolide may decrease the excretion rate of Migalastat which could result in a higher serum level.
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.
Milnacipran	Leuprolide may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Leuprolide may decrease the excretion rate of Milrinone which could result in a higher serum level.
Minocycline	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Minocycline.
Mirabegron	The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Leuprolide.
Mirtazapine	The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Leuprolide.
Mizolastine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mizolastine.
Mobocertinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mobocertinib.

Moexipril	The risk or severity of QTc prolongation can be increased when Moexipril is combined with Leuprolide.
Montelukast	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Montelukast.
Moricizine	The risk or severity of QTc prolongation can be increased when Moricizine is combined with Leuprolide.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin.
Moxisylyte	Leuprolide may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Muzolimine	Muzolimine may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Mycophenolate mofetil.
Mycophenolic acid	Leuprolide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
N-acetyltyrosine	Leuprolide may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Nadolol	Leuprolide may decrease the excretion rate of Nadolol which could result in a higher serum level.
Nafarelin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nafarelin.
Naldemedine	Leuprolide may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nalidixic acid.
Nalmefene	Leuprolide may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxone	Leuprolide may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naltrexone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Naltrexone.
Naproxen	Naproxen may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.
Nedaplatin	Leuprolide may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Leuprolide may decrease the excretion rate of Nedocromil which could result in a higher serum level.
Nefazodone	Leuprolide may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Nelfinavir	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Leuprolide.
Neomycin	Leuprolide may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Leuprolide may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Niacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Niacin.
Nicardipine	The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Leuprolide.
Nicorandil	Leuprolide may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nifedipine.
Nilotinib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilotinib.
Nilutamide	Leuprolide may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Nilvadipine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nilvadipine.
Nimesulide	Nimesulide may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Nimodipine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Nimodipine.
Nisoldipine	Leuprolide may decrease the excretion rate of Nisoldipine which could result in a higher serum level.
Nitrendipine	The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Leuprolide.
Nitric Oxide	Leuprolide may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.
Nitrofurantoin	Leuprolide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Nitroprusside	Leuprolide may decrease the excretion rate of Nitroprusside which could result in a higher serum level.
Nizatidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Nizatidine.
Norfloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Norfloxacin.
Nortriptyline	The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Leuprolide.
Octinoxate	Leuprolide may decrease the excretion rate of Octinoxate which could result in a higher serum level.
Octreotide	The risk or severity of QTc prolongation can be increased when Octreotide is combined with Leuprolide.
Ofloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ofloxacin.
Olanzapine	The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Leuprolide.
Olodaterol	The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Leuprolide.
Olsalazine	Olsalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ondansetron	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ondansetron.
Opium	Leuprolide may decrease the excretion rate of Opium which could result in a higher serum level.
Orphenadrine	The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Leuprolide.
Oseltamivir	Leuprolide may decrease the excretion rate of Oseltamivir which could result in a higher serum level.
Oxacillin	Leuprolide may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxaliplatin.
Oxaprozin	Oxaprozin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Oxatomide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxatomide.
Oxazepam	Leuprolide may decrease the excretion rate of Oxazepam which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Oxetacaine.
Oxybenzone	Leuprolide may decrease the excretion rate of Oxybenzone which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Oxybuprocaine.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Oxyquinoline	Leuprolide may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.
Oxytocin	The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Leuprolide.
Paclitaxel	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Paclitaxel.
Pacritinib	The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Leuprolide.
Paliperidone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Paliperidone.
Palonosetron	Leuprolide may decrease the excretion rate of Palonosetron which could result in a higher serum level.
Pamidronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pamidronic acid.
Panobinostat	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Panobinostat.
Pantoprazole	Leuprolide may decrease the excretion rate of Pantoprazole which could result in a higher serum level.
Papaverine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Papaverine.
Parecoxib	Parecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Paromomycin	Paromomycin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Pasireotide	The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Leuprolide.
Patent Blue	Leuprolide may decrease the excretion rate of Patent Blue which could result in a higher serum level.
Pazopanib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pazopanib.
Pefloxacin	The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Leuprolide.
Pegaptanib	Leuprolide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Leuprolide.
Pemetrexed	Leuprolide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Penbutolol	Leuprolide may decrease the excretion rate of Penbutolol which could result in a higher serum level.
Penicillamine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Penicillamine.
Pentaerythritol t	Leuprolide may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.
Pentamidine	The therapeutic efficacy of Pentamidine can be decreased when used in combination with Leuprolide.
Pentastarch	Leuprolide may decrease the excretion rate of Pentastarch which could result in a higher serum level.
Pentetic acid	Leuprolide may decrease the excretion rate of Pentetic acid which could result in a higher serum level.
Pentobarbital	Leuprolide may decrease the excretion rate of Pentobarbital which could result in a higher serum level.
Pentostatin	Leuprolide may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Pentoxifylline	Leuprolide may decrease the excretion rate of Pentoxifylline which could result in a higher serum level.
Perflutren	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Perflutren.
Perhexiline	The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Leuprolide.
Perindopril	Leuprolide may decrease the excretion rate of Perindopril which could result in a higher serum level.
Permethrin	Leuprolide may decrease the excretion rate of Permethrin which could result in a higher serum level.
Phenazopyridine	Phenazopyridine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Phenelzine	Leuprolide may decrease the excretion rate of Phenelzine which could result in a higher serum level.
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.
Pheniramine	The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Leuprolide.
Phenol	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Phenol.
Phentolamine	Leuprolide may decrease the excretion rate of Phentolamine which could result in a higher serum level.
Phenylbutazone	Phenylbutazone may decrease the excretion rate of Leuprolide which could result in a higher serum level.

Phenytoin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Phenytoin.
Pholcodine	Leuprolide may decrease the excretion rate of Pholcodine which could result in a higher serum level.
Phosphoric acid	Leuprolide may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.
Phylloquinone	Leuprolide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Picosulfuric acid	Leuprolide may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.
Pimozide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Pimozide.
Pinaverium	The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Leuprolide.
Pindolol	Leuprolide may decrease the excretion rate of Pindolol which could result in a higher serum level.
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.
Piperacillin	Leuprolide may decrease the excretion rate of Piperacillin which could result in a higher serum level.
Piracetam	Leuprolide may decrease the excretion rate of Piracetam which could result in a higher serum level.
Piretanide	Piretanide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Piroxicam	Piroxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Pitavastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pitavastatin.
Pitolisant	Leuprolide may increase the QTc-prolonging activities of Pitolisant.
Plazomicin	Leuprolide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Plerixafor	Leuprolide may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Polythiazide	Polythiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Pomalidomide	Leuprolide may decrease the excretion rate of Pomalidomide which could result in a higher serum level.
Ponesimod	The risk or severity of bradycardia can be increased when Ponesimod is combined with Leuprolide.
Posaconazole	The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Leuprolide.
Potassium	Potassium may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Potassium acetate	Leuprolide may decrease the excretion rate of Potassium acetate which could result in a higher serum level.
Potassium bicar	Leuprolide may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.
Potassium cation	Potassium cation may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Potassium chloride	Leuprolide may decrease the excretion rate of Potassium chloride which could result in a higher serum level.
Potassium citrate	Potassium citrate may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Potassium nitrate	Leuprolide may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.
Potassium perchlo	Leuprolide may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.
Potassium sulfate	Leuprolide may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.
Pralatrexate	Leuprolide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralidoxime	Leuprolide may decrease the excretion rate of Pralidoxime which could result in a higher serum level.
Pramipexole	Leuprolide may decrease the excretion rate of Pramipexole which could result in a higher serum level.
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Pramocaine.
Prasugrel	Leuprolide may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Pravastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Pravastatin.
Prednisone	Leuprolide may decrease the excretion rate of Prednisone which could result in a higher serum level.
Pregabalin	The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Leuprolide.
Prenylamine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prenylamine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Prilocaine.
Primaquine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Primaquine.
Probenecid	Leuprolide may decrease the excretion rate of Probenecid which could result in a higher serum level.
Probucol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Probucol.
Procainamide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Procainamide.
Procaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Procaine.
Procaine benzylp	Leuprolide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Procarbazine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Procarbazine.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Prochlorperazine.
Promazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Promazine.
Promethazine	The risk or severity of QTc prolongation can be increased when Promethazine is combined with Leuprolide.
Propafenone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Propafenone.
Propantheline	Leuprolide may decrease the excretion rate of Propantheline which could result in a higher serum level.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Proparacaine.
Propiverine	Leuprolide may decrease the excretion rate of Propiverine which could result in a higher serum level.
Propofol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Propoxycaine.
Propranolol	Leuprolide may decrease the excretion rate of Propranolol which could result in a higher serum level.
Propylthiouracil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Propylthiouracil.
Protriptyline	The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Leuprolide.
Prucalopride	Leuprolide may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Pyrantel	Leuprolide may decrease the excretion rate of Pyrantel which could result in a higher serum level.
Pyrazinamide	Leuprolide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Pyridoxine	Leuprolide may decrease the excretion rate of Pyridoxine which could result in a higher serum level.
Quetiapine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quetiapine.
Quinethazone	Quinethazone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Quinidine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinidine.
Quinine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Quinine.
Rabeprazole	Leuprolide may decrease the excretion rate of Rabeprazole which could result in a higher serum level.
Raltegravir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Raltegravir.
Ramelteon	Leuprolide may decrease the excretion rate of Ramelteon which could result in a higher serum level.
Ranitidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ranitidine.
Ranolazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ranolazine.
Rasagiline	Leuprolide may decrease the excretion rate of Rasagiline which could result in a higher serum level.
Relugolix	The risk or severity of QTc prolongation can be increased when Relugolix is combined with Leuprolide.
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.
Reserpine	Leuprolide may decrease the excretion rate of Reserpine which could result in a higher serum level.
Resorcinol	Leuprolide may decrease the excretion rate of Resorcinol which could result in a higher serum level.
Ribavirin	Leuprolide may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Ribociclib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ribociclib.
Ribostamycin	Leuprolide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilpivirine	The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Leuprolide.
Risedronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Risedronic acid.
Risperidone	The risk or severity of QTc prolongation can be increased when Risperidone is combined with Leuprolide.
Ritonavir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ritonavir.
Rivaroxaban	Leuprolide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rizatriptan	Leuprolide may decrease the excretion rate of Rizatriptan which could result in a higher serum level.
Rofecoxib	Rofecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Roflumilast	Leuprolide may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Romidepsin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Romidepsin.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Ropivacaine.
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.
Rosoxacin	The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Leuprolide.
Rosuvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Rosuvastatin.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Roxithromycin.
Rupatadine	The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Leuprolide.
Ruxolitinib	Leuprolide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Sacubitril	Leuprolide may decrease the excretion rate of Sacubitril which could result in a higher serum level.
Salbutamol	The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Leuprolide.
Salicylamide	Salicylamide may decrease the excretion rate of Leuprolide which could result in a higher serum level.

You Might Also Read Azithromycin safety; Is it safe for heart ? Answer from FDA

Salicylic acid	Salicylic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Salmeterol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Salmeterol.
Salmon calcit	Leuprolide may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Saquinavir	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Saquinavir.
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.
Secobarbital	Leuprolide may decrease the excretion rate of Secobarbital which could result in a higher serum level.
Selenious acid	Leuprolide may decrease the excretion rate of Selenious acid which could result in a higher serum level.
Selenium	Leuprolide may decrease the excretion rate of Selenium which could result in a higher serum level.
Semaglutide	The therapeutic efficacy of Semaglutide can be decreased when used in combination with Leuprolide.
Sevoflurane	The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Leuprolide.
Sibutramine	Leuprolide may decrease the excretion rate of Sibutramine which could result in a higher serum level.
Sildenafil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Sildenafil.
Simvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Simvastatin.
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.
Sodium acetate	Leuprolide may decrease the excretion rate of Sodium acetate which could result in a higher serum level.
Sodium aurothi	Leuprolide may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.
Sodium fluoride	Leuprolide may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.
Sodium sulfate	Leuprolide may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.
Sofosbuvir	Leuprolide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solifenacin	The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Leuprolide.
Solriamfetol	Leuprolide may decrease the excretion rate of Solriamfetol which could result in a higher serum level.
Somatotropin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Somatotropin.
Sorafenib	The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Leuprolide.
Sorbitol	Leuprolide may decrease the excretion rate of Sorbitol which could result in a higher serum level.
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Leuprolide.
Sotalol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sotalol.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sparfloxacin.
Spironolactone	Spironolactone may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Stavudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Stavudine.
Stiripentol	Leuprolide may decrease the excretion rate of Stiripentol which could result in a higher serum level.
Streptomycin	Leuprolide may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Strontium chloride	Leuprolide may decrease the excretion rate of Strontium chloride which could result in a higher serum level.
Sucralfate	Leuprolide may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Sulbactam	Leuprolide may decrease the excretion rate of Sulbactam which could result in a higher serum level.
Sulfadiazine	The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Leuprolide.
Sulfamethoxazole	The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Leuprolide.
Sulfasalazine	Sulfasalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Sulfisoxazole	The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Leuprolide.
Sulindac	Sulindac may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Sulpiride	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sulpiride.
Sultopride	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sultopride.
Sumatriptan	Leuprolide may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Sunitinib	The therapeutic efficacy of Sunitinib can be decreased when used in combination with Leuprolide.
Sy Estrogens, A	Leuprolide may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.
Synt Estrogens, B	Leuprolide may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.
Tacrine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrine.
Tacrolimus	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Tacrolimus.
Tadalafil	Leuprolide may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Tamoxifen	The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Leuprolide.
Tamsulosin	Leuprolide may decrease the excretion rate of Tamsulosin which could result in a higher serum level.
Tasimelteon	Leuprolide may decrease the excretion rate of Tasimelteon which could result in a higher serum level.
Technetium	Leuprolide may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.
Technetium Tc	Leuprolide may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.
Technetium Tc	Leuprolide may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.
Technetium Tc	Leuprolide may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Teduglutide	Leuprolide may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Tegafur	Leuprolide may decrease the excretion rate of Tegafur which could result in a higher serum level.
Telavancin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telavancin.
Telithromycin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Telithromycin.
Temazepam	Leuprolide may decrease the excretion rate of Temazepam which could result in a higher serum level.
Temozolomide	Leuprolide may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Tenofovir alafen	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Leuprolide.
Tenofovir disop	Tenofovir disoproxil may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Tenoxicam	Tenoxicam may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Terbinafine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Terbinafine.
Terbutaline	The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Leuprolide.
Terfenadine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terfenadine.
Terlipressin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Terlipressin.
Testolactone	Leuprolide may decrease the excretion rate of Testolactone which could result in a higher serum level.
Testosterone	Leuprolide may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone cypi	Leuprolide may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone enan	Leuprolide may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Testosterone prop	Leuprolide may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.
Testosterone und	Leuprolide may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Tetrabenazine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Tetracaine.
Tetracycline	Leuprolide may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Tetradecyl hydrog	Leuprolide may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Thiabendazole	Leuprolide may decrease the excretion rate of Thiabendazole which could result in a higher serum level.
Thiethylperazine	Leuprolide may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.
Thioridazine	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Thioridazine.
Thiothixene	The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Leuprolide.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Ticlopidine	Leuprolide may decrease the excretion rate of Ticlopidine which could result in a higher serum level.
Tiludronic acid	Leuprolide may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Timolol	The risk or severity of QTc prolongation can be increased when Timolol is combined with Leuprolide.
Tinidazole	Leuprolide may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Tiopronin	Leuprolide may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tiotropium	Leuprolide may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tirofiban	Leuprolide may decrease the excretion rate of Tirofiban which could result in a higher serum level.
Tirzepatide	The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Leuprolide.
Tixocortol	Leuprolide may decrease the excretion rate of Tixocortol which could result in a higher serum level.
Tizanidine	The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Leuprolide.
Tobramycin	Leuprolide may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tocopherol	Leuprolide may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.
Tolcapone	Leuprolide may decrease the excretion rate of Tolcapone which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Leuprolide which could result in a higher serum level.

Tolmetin	Tolmetin may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Tolterodine	The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Leuprolide.
Tolvaptan	Tolvaptan may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Topiramate	Leuprolide may decrease the excretion rate of Topiramate which could result in a higher serum level.
Topotecan	Leuprolide may decrease the excretion rate of Topotecan which could result in a higher serum level.
Torasemide	Torasemide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Toremifene	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Toremifene.
Tositumomab	Leuprolide may decrease the excretion rate of Tositumomab which could result in a higher serum level.
Trabectedin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trabectedin.
Tramadol	Leuprolide may decrease the excretion rate of Tramadol which could result in a higher serum level.
Trametinib	Leuprolide may decrease the excretion rate of Trametinib which could result in a higher serum level.
Trazodone	The risk or severity of QTc prolongation can be increased when Trazodone is combined with Leuprolide.
Treprostinil	The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Leuprolide.
Triamcinolone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triamcinolone.
Triamterene	Triamterene may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Triazolam.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Triclabendazole	The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Leuprolide.
Triethylenetetram	Leuprolide may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Trifluridine	Leuprolide may decrease the excretion rate of Trifluridine which could result in a higher serum level.
Trimebutine	The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Leuprolide.
Trimethadione	The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Leuprolide.
Trimethoprim	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Trimethoprim.
Trimetrexate	Leuprolide may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Trimipramine	The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Leuprolide.
Triprolidine	The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Leuprolide.
Triptorelin	The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Leuprolide.
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.
Tropisetron	Leuprolide may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Trovafloxacin.
Ubidecarenone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Ubidecarenone.
Vaborbactam	Leuprolide may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Valbenazine	Leuprolide may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Leuprolide which could result in a higher serum level.
Valganciclovir	Leuprolide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valproic acid	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid.
Vancomycin	Leuprolide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Vandetanib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vandetanib.
Vardenafil	The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Leuprolide.
Varenicline	Leuprolide may decrease the excretion rate of Varenicline which could result in a higher serum level.
Vemurafenib	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Vemurafenib.
Venlafaxine	Leuprolide may decrease the excretion rate of Venlafaxine which could result in a higher serum level.
Verapamil	Leuprolide may decrease the excretion rate of Verapamil which could result in a higher serum level.
Vernakalant	The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Leuprolide.
Vilanterol	The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Leuprolide.
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.
Viloxazine	Leuprolide may decrease the excretion rate of Viloxazine which could result in a higher serum level.
Vincristine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Vincristine.
Voriconazole	The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Leuprolide.
Vorinostat	The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Leuprolide.
Vortioxetine	Leuprolide may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Warfarin	Leuprolide may decrease the excretion rate of Warfarin which could result in a higher serum level.
Zaleplon	Leuprolide may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Zanamivir	Leuprolide may decrease the excretion rate of Zanamivir which could result in a higher serum level.
Zidovudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Zidovudine.
Ziprasidone	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Ziprasidone.
Zonisamide	Zonisamide may increase the excretion rate of Leuprolide which could result in a lower serum level and potentially a reduction in efficacy.
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Zuclopenthixol.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. Therefore, the possibility exists that spontaneous abortion may occur if the drug is administered during pregnancy. If this drug is administered during pregnancy or if the patient becomes pregnant while taking any formulation of leuprolide acetate, the patient should be apprised of the potential hazard to the fetus

Lactation

Nursing Mothers: It is not known whether leuprolide acetate is excreted in human milk. Leuprolide acetate should not be used by nursing mothers.

Why is this medication prescribed?

Leuprolide injection (Eligard, Lupron Depot) is used to treat the symptoms associated with advanced prostate cancer. Leuprolide injection (Lupron Depot-PED, Fensolvi) is used in children 2 years of age or older to treat central precocious puberty (CPP; a condition causing girls [usually younger than 8 years of age] and boys [usually younger than 9 years of age] to enter puberty too soon, resulting in faster than normal bone growth and development of sexual characteristics). Leuprolide injection (Lupron Depot) is used alone or with another medication (norethindrone) to treat endometriosis (a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes pain, heavy or irregular menstruation [periods], and other symptoms). Leuprolide injection (Lupron Depot) is also used with other medication to treat anemia (a lower-than-normal number of red blood cells) caused by uterine fibroids (noncancerous growths in the uterus). Leuprolide injection is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the number of certain hormones in the body.

How should this medicine be used?

Leuprolide injection comes as a long-acting suspension (Lupron) that is injected intramuscularly (into a muscle) by a doctor or nurse in a medical office or clinic and is usually given once a month (Lupron Depot, Lupron Depot-PED) or every 3, 4, or 6 months (Lupron Depot-3 month, Lupron Depot-PED-3 month, Lupron Depot-4 month, Lupron Depot-6 Month). Leuprolide injection also comes as a long-acting suspension (Eligard) that is injected subcutaneously (just under the skin) by a doctor or nurse in a medical office or clinic and is usually given every 1, 3, 4, or 6 months. Leuprolide injection also comes as a long-acting suspension (Fensolvi) that is injected subcutaneously (just under the skin) by a doctor or nurse in a medical office or clinic and is usually given every 6 months. Your doctor will tell you how long your treatment with leuprolide injection will last. When used in children with precocious puberty, leuprolide injection (Lupron Depot-PED, Lupron Depot-PED-3 month, Fensolvi) will likely be stopped by your child’s doctor before 11 years of age in girls and 12 years of age in boys.

If you receive leuprolide long-acting suspension (Eligard) as a subcutaneous injection, you may notice a small bump at the place where the injection was given when you first receive the medication. This bump should eventually go away.

Leuprolide may cause an increase in certain hormones in the first few weeks after injection. Your doctor will monitor you carefully for any new or worsening symptoms during this time. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before receiving a leuprolide injection,

tell your doctor and pharmacist if you are allergic to leuprolide, goserelin (Zoladex), histrelin (Supprelin LA, Vantas), nafarelin (Synarel), triptorelin (Triptodur, Trelstar), any other medications, or any of the ingredients in leuprolide injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: certain medications for irregular heartbeat such as amiodarone (Cordarone), disopyramide (Norpace), procainamide (Procanbid), quinidine, and sotalol (Betapace, Betapace AF, Sorine); bupropion (Aplenzin, Forfivo, Wellbutrin, in Contrave); medications for seizures; oral steroids such as dexamethasone (Hemady), methylprednisolone (Medrol), and prednisone (Rayos); and selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, in Symbyax), fluvoxamine (Luvox), paroxetine (Brisdelle, Paxil), and sertraline (Zoloft). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with leuprolide, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you have unusual vaginal bleeding. Your doctor may tell you not to use leuprolide injection.
tell your doctor if you or anyone in your family has or has ever had osteoporosis (a condition where bones are thin and more likely to break); if you have a history of drinking alcohol or using tobacco products for a long period of time; or if you have or have ever had depression, seizures, brain tumors, cancer that has spread to the spine (backbone), diabetes, urinary obstruction (blockage that causes difficulty urinating), blood in your urine, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), cerebrovascular disease (clogging or weakening of the blood vessels within the brain or leading to the brain), heart disease, or a low level of potassium, calcium, or magnesium in your blood.
you should know that leuprolide is not to be used in women who are pregnant, can become pregnant, or are breastfeeding. Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Your doctor may perform a pregnancy test to be sure that you are not pregnant when you begin receiving leuprolide injections. You will need to use a reliable nonhormonal method of birth control to prevent pregnancy while you are receiving a leuprolide injection. Talk to your doctor about the types of birth control that are right for you, and continue to use birth control even though you should not have regular menstrual periods during your treatment. If you think you have become pregnant while receiving a leuprolide injection, call your doctor immediately. Leuprolide injection can harm the fetus.

References

Leuprolide – Uses, Dosage, Side Effects, Interaction

Mechanism of Action

Indications

Contraindications